Lymphoma Regression Induced by Ganciclovir in Mice Bearing a Herpes Thymidine Kinase Transgene

Human Gene Therapy

Volumn 1, Issue 2, 1990, Pages 125-134

  Moolten, Frederick L ^a,b   Wells, John M ^a,b   Heyman, Richard A ^c   Evans, Ronald M ^c  

^a Center for Health Quality Outcomes and Economic Research Edith Nourse Rogers Memorial Veterans Hospital   (United Kingdom)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL; ARTICLE; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; GENE THERAPY; GENETICS; HERPES SIMPLEX VIRUS; LYMPHOCYTE; LYMPHOMA; METABOLISM; MOUSE; TRANSGENIC MOUSE; VIRUS GENE;

ANIMAL; GANCICLOVIR; GENE THERAPY; GENES, VIRAL; LYMPHOCYTES; LYMPHOMA; MICE; MICE, TRANSGENIC; SIMPLEXVIRUS; SUBSTRATE SPECIFICITY; SUPPORT, U.S. GOV'T, NON-P.H.S.; THYMIDINE KINASE;

ABELSON LEUKEMIA VIRUS; HERPES; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 0025444099     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.1990.1.2-125     Document Type: Article

References (26)

1. BALZARINI, J., DE CLERCQ, E., VERBRUGGEN, A., AYUSAWA, D., and SENO, T. (1985). Highly cytostatic activity of (E)-5-(2-bromovinyi)-2′-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene. Mol. Pharmacol. 28, 581–587.
2. BISHOP, J.M. (1987). The molecular genetics of cancer. Science 235, 305–311.
3. BORRELLI, E., HEYMAN, R., HSI, M., and EVANS, R.M. (1988). Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. USA 85, 7572–7576.
4. BORRELLI, E., HEYMAN, R., ARIAS, C., SAWCHENKO, P.E., and EVANS, R.M. (1989). Transgenic mice with inducible dwarfism. Nature 339, 538–541.
5. BRINSTER, R.L., CHEN, H.Y.,TRUMBAUER, M., SENEAR, A.W., WARREN, R., and PALMITER, R.D. (1981). Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 27, 223–231.
6. CLINE, M.J., STANG, H., MERCOLA, K., MORSE, L., RUPRECHT, R., BROWNE, J., and SALSER, W. (1980). Gene transfer in intact animals. Nature 284, 422–425.
7. DAVIDSON, R.L., KAUFMAN, E.R., CRUMPACKER, C.S., and SCHNIPPER, L.E. (1981). Inhibition of herpes simplex virus transformed and nontransformed cells by acycloguanosine: mechanisms of uptake and toxicity. Virology 113,9–19.
8. ELION, G.B. (1980). The chemotherapeutic exploitation of virus-specified enzymes. Advances Enzy. Regul. 18,53–66.
9. ELION, G.B., FURMAN, P.A., FYFE, J.A., DE MIRANDA, P., BEAUCHAMP, L., and SCHAEFFER, H.J. (1977). Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA 74, 5716–5720.
10. FIELD, A.K., DA VIES, M.E., DE WITT, C., PERRY, H.C., LIOU, R., GERMERSHAUSEN, J., KARKAS, J.D., ASHTON, W.T., JOHNSTON, D.B.R., and TOLMAN, R.L., (1983). 9-{[2-Hydroxy-1-(hydroxymethyl) ethoxy]methyl}guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA 80, 4139–4143.
11. FURMAN, P.A., Mcguirt, P. V., KELLER, P.M., FYFE, J. A., and ELION, G.B. (1980). Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology 102, 420–430.
12. GREEN, P., KAEHLER, D., and RISSER, R. (1987). Cell transformation and tumor induction by Abelson murine leukemia virus in the absence of helper virus. Proc. Natl. Acad. Sci. USA 84, 5932–5936.
13. HEYMAN, R.A., BORRELLI, E., LESLEY, J., ANDERSON, D., RICHMAN, D.D., BAIRD, S.M., HYMAN, R., and EVANS, R.M. (1989). Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc. Natl. Acad. Sci. USA 86, 2698–2702.
14. HOGAN, B., COSTANTINI, F., and LACY, E., eds. (1986). Manipulating the Mouse Embryo: a Laboratory Manual. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) pp. 174–176.
15. ISOLA, L.M., and GORDON, J.W. (1986). Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene. Proc. Natl. Acad. Sci. USA 83, 9621–9625.
16. KALLMAN, R.F., BROWN, J.M., DENEKAMP, J., HILL, R.P., KUMMERMEHR, J., and TROTT, K.R. (1985). The use of rodent tumors in experimental cancer therapy. Cancer Res. 45, 6541–6544.
17. Medical Research Council, London. (1988). UK Coordinating Committee on Cancer Research: guidelines for the welfare of animals in experimental neoplasia.
18. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer. Res. 46, 5276–5281.
19. MOOLTEN, F.L. (1990). Mosaicism induced by gene insertion as a means of improving chemotherapeutic selectivity. Crit. Rev. Immunol. 10, 203–233.
20. MOOLTEN, F.L., and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297–300.
21. NISHIYAMA, Y., and RAPP, F. (1979). Anticellular effects of 9-(2-hydroxy-ethoxymethyl)guanine against herpes simplex virus-transformed cells. J. Gen. Virol. 45, 227–230.
22. OLIVER, S., BUBLEY, G., and CRUMPACKER, C. (1985). Inhibition of HSV-transformed murine cells by nucleoside analogs, 2′NDG and 2′nor-cGMP: mechanisms of inhibition and reversal by exogenous nucleosides. Virology 145, 84–93.
23. SANZ, G.F., SANZ, M.A., VALLESPI, T., CANIZO, M.C., TORRABADELLA, M., GARCIA, S., IRRIGUIBLE, D., and SAN MIGUEL, J.F. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74, 395–408.
24. SMEE, D.F., MARTIN, J.C., VERHEYDEN, J. P. H., and MATTHEWS, T.R. (1983). Anti-herpesvirus activity of the acyclic nucleoside 9-(l-3-dihydroxy-2-propoxy-methyl)guanine. Antimicrob. Agents Chemother. 23, 676–682.
25. SMITH, K.O., GALLOWAY, K.S., KENNELL, W.L., OGILVIE, K.K., and RADATUS, B.K. (1982). A new nucleoside analog, 9-{[2-hydroxy-l-(hydroxymethyl)ethoxy]-methyl}guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 22, 55–61.
26. WILLIAMS, D.A., HSIEH, K., Desilva, A., and MULLIGAN, R.C. (1987). Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J. Exp. Med. 166,210–218.